Pimobendan
CAS No. 74150-27-9
Pimobendan( UD-CG 115 )
Catalog No. M15830 CAS No. 74150-27-9
Pimobendan is a selective inhibitor of PDE3 with IC50 of 0.32 μM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 58 | In Stock |
|
| 5MG | 38 | In Stock |
|
| 10MG | 53 | In Stock |
|
| 25MG | 77 | In Stock |
|
| 50MG | 100 | In Stock |
|
| 100MG | 137 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 198 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePimobendan
-
NoteResearch use only, not for human use.
-
Brief DescriptionPimobendan is a selective inhibitor of PDE3 with IC50 of 0.32 μM.
-
DescriptionPimobendan is a selective inhibitor of PDE3 with IC50 of 0.32 μM.(In Vitro):Pimobendan (UD-CG115) exhibits selective inhibition of PDE III isolated from guinea pig cardiac muscle with IC50 of 0.32 uM compared to the inhibition of PDE I and PDE II (IC50 >30 μM). In human atrial cells, 100 μM Pimobendan (UD-CG115) significantly increases the L-type calcium current (ICa(L)) (evoked by depolarization to +10 mV from a holding potential of -40 mV) by 250.4% with the half-maximal stimulation (EC50 ) of 1.13 μM. In rabbit atrial cells, Pimobendan (UD-CG115) increases ICa(L) at +10 mV by 67.4.%, which is significantly lower than that obtained in human atrial cells.(In Vivo):Pimobendan (UD-CG115) shows a beneficial effect on survival in the murine model of EMC virus-induced myocarditis. Administration of Pimobendan (UD-CG115) significantly increases the final survival rate from 33.6% (control) to 53.3% (0.1 mg/kg) or 66.7% (1 mg/kg). Pimobendan (UD-CG115) (1 mg/kg) also significantly reduces myocardial cellular infiltration, the level of intracardiac tumor necrosis factor (TNF)-α and interleukin (IL)-1β compared with the control group, which shows no effect on myocardial necrosis, heart weight and body weight. Pimobendan (UD-CG115) suppresses expression of the intracardiac iNOS gene , causing reduction of intracardiac NO production.
-
In VitroPimobendan (UD-CG115) exhibits selective inhibition of PDE III isolated from guinea pig cardiac muscle with IC50 of 0.32 uM compared to the inhibition of PDE I and PDE II (IC50 >30 μM). In human atrial cells, 100 μM Pimobendan (UD-CG115) significantly increases the L-type calcium current (ICa(L)) (evoked by depolarization to +10 mV from a holding potential of -40 mV) by 250.4% with the half-maximal stimulation (EC50 ) of 1.13 μM.In rabbit atrial cells, Pimobendan (UD-CG115) increases ICa(L) at +10 mV by 67.4.%, which is significantly lower than that obtained in human atrial cells.
-
In VivoPimobendan (UD-CG115) shows a beneficial effect on survival in the murine model of EMC virus-induced myocarditis. Administration of Pimobendan (UD-CG115) significantly increases the final survival rate from 33.6% (control) to 53.3% (0.1 mg/kg) or 66.7% (1 mg/kg). Pimobendan (UD-CG115) (1 mg/kg) also significantly reduces myocardial cellular infiltration, the level of intracardiac tumor necrosis factor (TNF)-α and interleukin (IL)-1β compared with the control group, which shows no effect on myocardial necrosis, heart weight and body weight. Pimobendan (UD-CG115) suppresses expression of the intracardiac iNOS gene , causing reduction of intracardiac NO production.
-
SynonymsUD-CG 115
-
PathwayAngiogenesis
-
TargetPDE
-
RecptorPDE3
-
Research AreaCardiovascular Disease
-
Indication——
Chemical Information
-
CAS Number74150-27-9
-
Formula Weight334.37
-
Molecular FormulaC19H18N4O2
-
Purity>98% (HPLC)
-
SolubilityEthanol: 5 mg/mL (14.95 mM); DMSO: 67 mg/mL (200.37 mM)
-
SMILESO=C1CC(C)C(C2=CC=C3C(NC(C4=CC=C(OC)C=C4)=N3)=C2)=NN1
-
Chemical Name3-[2-(4-methoxyphenyl)-3H-benzimidazol-5-yl]-4-methyl-4,5-dihydro-1H-pyridazin-6-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Beier N, et al. J Cardiovasc Pharmacol, 1991, 18(1), 17-27.
molnova catalog
related products
-
BI 1015550
Nerandomilast (BI 1015550) is an orally active PDE4B inhibitor with IC50 of 7.2 nM. BI 1015550 has potential applications in inflammation, allergic diseases, pulmonary fibrosis and chronic obstructive pulmonary disease (COPD) with a good safety profile.
-
MY-5445
MY-5445 is a specific inhibitor of phosphodiesterase type 5 (PDE5). MY-5445 selectively inhibits cGMP PDE (Ki:1.3 μM).
-
Dovramilast
Dovramilast (CC-11050) is an orally active phosphodiesterase 4 (PDE4) inhibitor that reduces the production of pro-inflammatory mediators and cytokines.
Cart
sales@molnova.com